Experience

• • Lorax in the formation of LCP Fund II, a $253 million Egypt-focused private equity fund.
  • Pantheon as co-lead investor in a €708 million continuation fund, sponsored by DPE Deutsche Private Equity, to invest in two European technology and digital transformation consultancies. The deal won “Secondaries Deal of the Year” in Europe in the Secondaries Investor annual awards.
  • Clayton, Dubilier & Rice in the financing aspects of its acquisitions of Atalian and OCS to create a global facilities management platform.
  • Apera Asset Management in the formation of Apera Private Debt Fund II, a €1.27 billion pan-European mid-market private debt fund.
  • AfricInvest in the formation of AfricInvest Fund IV, its largest ever Africa-focused fund with total commitments of $411 million.
  • Norilsk Nickel in its $500 million Eurobond offering of 2.80% notes due 2026.
  • PJSC Polyus in its $700 million Eurobond offering of 3.25% notes due 2028 and a related tender offer for outstanding notes due 2023 and 2024 for the aggregate principal amount of $605.3 million.
  • Development Partners International in the formation of African Development Partners III Fund, a $900 million fund investing in innovation-led companies in Africa.
  • Clayton, Dubilier & Rice in financing aspects of its £7 billion recommended cash offer for Morrisons.
  • NLMK in its €500 million Eurobond offering of 1.45% notes due 2026 and a related tender offer for outstanding notes due 2023 and 2024 for the aggregate principal amount of $470.6 million.
  • A prominent New York family office in a separately managed account arrangement targeting venture investments in technology-oriented companies in Africa.
  • The lead investor in an approximately $120 million continuation fund, sponsored by a leading Israeli private equity sponsor, to acquire multiple assets from an end of term fund.
  • A major international financial investor in the formation of a €1 billion+ global infrastructure fund.
  • Goldman Sachs Asset Management and Pantheon as co-underwriters of CapVest Strategic Opportunities, a €1.2 billion continuation vehicle sponsored by CapVest for the single-asset fund restructuring of its portfolio company, Curium Pharma.
  • LeapFrog Investments in its $500 million partnership with Temasek, including Temasek taking a minority stake in LeapFrog, and a multi-fund investment by Temasek to anchor LeapFrog’s future funds.
  • Pantheon and LGT Capital Partners as lead investors in a continuation vehicle sponsored by Medicxi, a European life sciences investor, involving six preclinical- and clinical-stage assets.
  • Norilsk Nickel in its $500 million Eurobond offering of 2.55% notes due 2025.
  • Exponent in a £125 million preferred equity facility for Exponent Private Equity Partners III, a £1 billion buyout fund.
  • Metric Capital Partners in the formation of MCP Private Capital Fund IV, a €1.2 billion European special opportunities fund.
  • Pantheon in its equity investment as part of the proposed £2 billion takeover by KKR of John Laing Group plc.
  • GHO Capital Partners in the formation of GHO Capital Fund II, a €975 million fund which was Europe’s largest ever healthcare fund at the time of closing.
  • HarbourVest Partners as lead investor in the GP-led restructuring of Bridgepoint Capital’s €4.8 billion crisis-era fund, Bridgepoint Europe IV.
  • Norilsk Nickel in its $750 million Eurobond offering of 3.375% notes due 2024.
  • LGT Capital Partners in the formation of Crown Global Secondaries V, a $4.5 billion private equity secondaries fund.
  • NLMK in its $500 million Eurobond offering of 4.70% notes due 2026.
  • LeapFrog Investments in the formation of LeapFrog Emerging Consumer Fund III, a $700 million emerging markets-focused impact fund.
  • DBAY Advisors in the formation of DouglasBay Capital III Fund, a European fund making investments in small and micro-cap listed companies.
  • Apera Asset Management in the formation of its €750 million private debt platform, focussing on senior secured loans to lower mid-market businesses in German-speaking Europe, France, Benelux, the UK and Northern Europe.
  • Canson in the formation of its $100 million co-investment fund, which will co-invest in the acquisition of a majority stake in the Financial and Risk division of Thomson Reuters.
  • Norilsk Nickel in its up to $2.5 billion syndicated term loan facility with an international syndicate comprising 17 banks and financial institutions.
  • NLMK in its $500 million Eurobond offering of 4% notes due 2024, and a related tender offer for outstanding notes due 2018 and 2019 for the aggregate principal amount of $317 million.
  • Metric Capital Partners in its €100 million subscription facility with Citibank.
  • Nornickel in its $1 billion Eurobond offering of 4.10% notes due 2023.
  • Metric Capital Partners in the formation of MCP Private Capital Fund III, an €850 million European special opportunities fund.
  • NLMK and its U.S. subsidiaries in a $250 million ABL facility.
  • Polyus Gold International in its $500 million Eurobond offering of 4.699% notes due 2022.
  • PartnerRe in its €750 million debut Eurobond offering of 1.25% notes due 2026.
  • NLMK in its $700 million Eurobond offering of 4.5% loan participation notes due 2023, and a related tender offer for its outstanding notes due 2018 and 2019 for the aggregate principal amount of $571 million.
  • Park Square in the formation of Park Square Capital Partners III, a €1.2 billion subordinated debt fund.
  • HarbourVest Partners in its co-investment with IK Investment Partners in the Salad Signature group, a Dutch and Belgian food business.
  • Prudential Financial in its $350 million partnership with LeapFrog Investments, targeting investments in life insurance companies in Africa.
  • NLMK in its $400 million pre-export finance facility.
  • Norilsk Nickel in its $1 billion Eurobond offering of 6.625% notes due 2022.
  • Lannett in its acquisition for $1.23 billion in cash, plus additional contingent consideration, of Kremers Urban Pharmaceuticals, the U.S. specialty generic pharmaceuticals subsidiary of global biopharmaceuticals company UCB.
  • Park Square in the formation of Park Square Capital Credit Opportunities II, a $2.4 billion senior debt programme.
  • NLMK Europe Plate Division in its €250 million revolving collateralized credit facility.
  • AXA in the sale of its mandatory pension business in Hong Kong to the Principal Financial Group.
  • Exponent Private Equity Partners in the formation of Exponent Private Equity Partners III, a £1 billion UK buyout fund.
  • HarbourVest Partners as a selling shareholder, together with Exponent, in the purchase of Trainline by KKR.
  • Knighthead Capital Management in its formation and capitalization of Knighthead Holdings Ltd., a Cayman Islands-based annuity provider.
  • Ares Management in the formation of Ares Europe Real Estate Fund IV, a $1.3 billion Europe real estate fund.
  • Clayton, Dubilier & Rice in tax aspects of its €1.2 billion acquisition of Mauser Group, a leading provider of industrial packaging.
  • A consortium including HarbourVest Partners and Coller Capital, in their secondary purchase of interests in Absa Capital Private Equity Fund I from Barclays Africa Group, formerly known as Absa Capital, as part of a spin-out of Absa Capital Private Equity from the Absa Group.
  • AREA in its formation of its European real estate funds.
  • Eutelsat in its $1.14 billion acquisition of Satélites Mexicanos.